Invitae Corporation (NVTA): Price and Financial Metrics
GET POWR RATINGS... FREE!
NVTA Price/Volume Stats
| Current price | $1.06 | 52-week high | $9.00 |
| Prev. close | $1.08 | 52-week low | $1.03 |
| Day low | $1.03 | Volume | 8,835,300 |
| Day high | $1.09 | Avg. volume | 8,356,819 |
| 50-day MA | $1.30 | Dividend yield | N/A |
| 200-day MA | $2.24 | Market Cap | 276.32M |
NVTA Stock Price Chart Interactive Chart >
NVTA POWR Grades
- Growth is the dimension where NVTA ranks best; there it ranks ahead of 95.41% of US stocks.
- NVTA's strongest trending metric is Quality; it's been moving up over the last 179 days.
- NVTA's current lowest rank is in the Sentiment metric (where it is better than 2.47% of US stocks).
NVTA Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for NVTA is -13.91 -- better than just 1.45% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, INVITAE CORP is reporting a growth rate of 566.87%; that's higher than 97.1% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for NVTA comes in at 40.36% -- higher than that of 95.65% of stocks in our set.
- Stocks that are quantitatively similar to NVTA, based on their financial statements, market capitalization, and price volatility, are KOS, KERN, KN, MUR, and SM.
- NVTA's SEC filings can be seen here. And to visit INVITAE CORP's official web site, go to www.invitae.com.
NVTA Valuation Summary
- In comparison to the median Healthcare stock, NVTA's price/sales ratio is 88.24% lower, now standing at 0.6.
- NVTA's EV/EBIT ratio has moved up 18.2 over the prior 101 months.
Below are key valuation metrics over time for NVTA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NVTA | 2023-05-23 | 0.6 | -8.7 | -0.1 | -0.6 |
| NVTA | 2023-05-22 | 0.6 | -8.0 | -0.1 | -0.6 |
| NVTA | 2023-05-19 | 0.6 | -7.7 | -0.1 | -0.6 |
| NVTA | 2023-05-18 | 0.6 | -8.1 | -0.1 | -0.6 |
| NVTA | 2023-05-17 | 0.6 | -8.3 | -0.1 | -0.6 |
| NVTA | 2023-05-16 | 0.6 | -8.3 | -0.1 | -0.6 |
NVTA Growth Metrics
- Its 4 year cash and equivalents growth rate is now at 100.6%.
- Its 5 year cash and equivalents growth rate is now at 100.6%.
- The year over year net income to common stockholders growth rate now stands at 26.38%.
The table below shows NVTA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 519.97 | -586.852 | -3,211.6 |
| 2022-06-30 | 500.829 | -623.202 | -3,108.62 |
| 2022-03-31 | 480.519 | -617.838 | -451.373 |
| 2021-12-31 | 460.449 | -559.815 | -379.006 |
| 2021-09-30 | 434.759 | -497.479 | -408.22 |
| 2021-06-30 | 389.092 | -394.593 | -312.946 |
NVTA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NVTA has a Quality Grade of D, ranking ahead of 13.88% of graded US stocks.
- NVTA's asset turnover comes in at 0.118 -- ranking 73rd of 81 Healthcare stocks.
- BKD, VCYT, and HCSG are the stocks whose asset turnover ratios are most correlated with NVTA.
The table below shows NVTA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.118 | 0.281 | -0.331 |
| 2021-03-31 | 0.139 | 0.268 | -0.887 |
| 2020-12-31 | 0.183 | 0.291 | -1.070 |
| 2020-09-30 | 0.284 | 0.321 | -0.721 |
| 2020-06-30 | 0.280 | 0.347 | -0.790 |
| 2020-03-31 | 0.336 | 0.429 | -0.705 |
Invitae Corporation (NVTA) Company Bio
Invitae Corporation is a company that utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for physicians and their patients. The company was founded in 2012 and is based in San Francisco, California.
Latest NVTA News From Around the Web
Below are the latest news stories about INVITAE CORP that investors may wish to consider to help them evaluate NVTA as an investment opportunity.
Natera wins $19 million US verdict from ArcherDX in cancer-detection patent caseGenetic testing company Natera Inc convinced a Delaware federal jury on Monday to award it $19.3 million in damages from Invitae Corp's ArcherDX for infringing patents related to cancer detection. The jury agreed with Natera that biotech company ArcherDX Inc's blood-based DNA tests for detecting and monitoring cancer infringed three of its patents. The award was just over half of the $38 million Natera had requested, according to court documents. |
Natera wins $19 mln US verdict from ArcherDX in cancer-detection patent caseGenetic testing company Natera Inc convinced a Delaware federal jury on Monday to award it $19.3 million in damages from Invitae Corp's ArcherDX for infringing patents related to cancer detection. The jury agreed with Natera that biotech company ArcherDX Inc's blood-based DNA tests for detecting and monitoring cancer infringed three of its patents. The award was just over half of the $38 million Natera had requested, according to court documents. |
Invitae to Appeal Trial VerdictInvitae (NYSE: NVTA), a leading medical genetics company, today announced that it intends to appeal the verdict delivered by a jury at the United States District Court for the District of Delaware. The jury found that Invitae's products using Anchored Multiplex PCR ("AMP") chemistry infringe certain Natera, Inc. patents. The jury awarded Natera a total of $19.35 million, based on lost profits and a royalty rate of 10% on certain products. Invitae will vigorously defend itself in future proceedin |
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtCathie Wood as an investor reminds me of the protagonists in the tornado-chasing classic Twister. The co-founder, CEO, and main stock picker of Ark Invest was active in the market windstorm on Wednesday, and thankfully for us, she posts her daily transactions at the end of every trading day. Wood added to her positions in Twilio (NYSE: TWLO), Palantir (NYSE: PLTR), and Invitae (NYSE: NVTA) on Wednesday. |
Invitae (NVTA) Q1 2023 Earnings Call TranscriptJoining us today are president and CEO, Ken Knight; our CFO, Roxi Wen and our chief science officer, Dr. Robert Daber. Before we begin, I'd like to remind you that various remarks that we make on this call that are not historical includes those about our vision and business model, the company's strategic business realignment, future financial and operating results; expectations of future growth and reduction in burn rates, and future products, services of our product pipeline and the timing. |
NVTA Price Returns
| 1-mo | -22.06% |
| 3-mo | -47.52% |
| 6-mo | -59.85% |
| 1-year | -73.63% |
| 3-year | -93.82% |
| 5-year | -85.58% |
| YTD | -43.01% |
| 2022 | -87.82% |
| 2021 | -63.48% |
| 2020 | 159.21% |
| 2019 | 45.84% |
| 2018 | 21.81% |
Continue Researching NVTA
Want to do more research on Invitae Corp's stock and its price? Try the links below:Invitae Corp (NVTA) Stock Price | Nasdaq
Invitae Corp (NVTA) Stock Quote, History and News - Yahoo Finance
Invitae Corp (NVTA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...